Medical innovation is blooming in 2024, and it has the potential to positively impact many patients. The end of 2023 brought the first FDA treatment using groundbreaking CRISPR gene editing technology ...
ALPS Medical Breakthroughs ETF (SBIO) targets late-stage clinical biotech firms poised for FDA approval or acquisition, offering high-risk, high-reward exposure. SBIO surged 91% over the past year, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results